FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226242524> ?p ?o ?g. }

• W4226242524 endingPage "1779" @default.
• W4226242524 startingPage "1764" @default.
• W4226242524 abstract "Background: Cardiac troponin (cTn) T and cTnI are considered cardiac specific and equivalent in the diagnosis of acute myocardial infarction. Previous studies suggested rare skeletal myopathies as a noncardiac source of cTnT. We aimed to confirm the reliability/cardiac specificity of cTnT in patients with various skeletal muscle disorders (SMDs). Methods: We prospectively enrolled patients presenting with muscular complaints (≥2 weeks) for elective evaluation in 4 hospitals in 2 countries. After a cardiac workup, patients were adjudicated into 3 predefined cardiac disease categories. Concentrations of cTnT/I and resulting cTnT/I mismatches were assessed with high-sensitivity (hs-) cTnT (hs-cTnT–Elecsys) and 3 hs-cTnI assays (hs-cTnI–Architect, hs-cTnI–Access, hs-cTnI–Vista) and compared with those of control subjects without SMD presenting with adjudicated noncardiac chest pain to the emergency department (n=3508; mean age, 55 years; 37% female). In patients with available skeletal muscle biopsies, TNNT/I1-3 mRNA differential gene expression was compared with biopsies obtained in control subjects without SMD. Results: Among 211 patients (mean age, 57 years; 42% female), 108 (51%) were adjudicated to having no cardiac disease, 44 (21%) to having mild disease, and 59 (28%) to having severe cardiac disease. hs-cTnT/I concentrations significantly increased from patients with no to those with mild and severe cardiac disease for all assays (all P <0.001). hs-cTnT–Elecsys concentrations were significantly higher in patients with SMD versus control subjects (median, 16 ng/L [interquartile range (IQR), 7–32.5 ng/L] versus 5 ng/L [IQR, 3–9 ng/L]; P <0.001), whereas hs-cTnI concentrations were mostly similar (hs-cTnI–Architect, 2.5 ng/L [IQR, 1.2–6.2 ng/L] versus 2.9 ng/L [IQR, 1.8–5.0 ng/L]; hs-cTnI–Access, 3.3 ng/L [IQR, 2.4–6.1 ng/L] versus 2.7 ng/L [IQR, 1.6–5.0 ng/L]; and hs-cTnI–Vista, 7.4 ng/L [IQR, 5.2–13.4 ng/L] versus 7.5 ng/L [IQR, 6–10 ng/L]). hs-cTnT–Elecsys concentrations were above the upper limit of normal in 55% of patients with SMD versus 13% of control subjects ( P <0.01). mRNA analyses in skeletal muscle biopsies (n=33), mostly (n=24) from individuals with noninflammatory myopathy and myositis, showed 8-fold upregulation of TNNT2 , encoding cTnT (but none for TNNI3 , encoding cTnI) versus control subjects (n=16, P Wald <0.001); the expression correlated with pathological disease activity ( R =0.59, P t-statistic <0.001) and circulating hs-cTnT concentrations ( R =0.26, P t-statistic =0.031). Conclusions: In patients with active chronic SMD, elevations in cTnT concentrations are common and not attributable to cardiac disease in the majority. This was not observed for cTnI and may be explained in part by re-expression of cTnT in skeletal muscle. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03660969." @default.
• W4226242524 created "2022-05-05" @default.
• W4226242524 creator A5000794291 @default.
• W4226242524 creator A5006190744 @default.
• W4226242524 creator A5008204005 @default.
• W4226242524 creator A5010633320 @default.
• W4226242524 creator A5014051857 @default.
• W4226242524 creator A5017457151 @default.
• W4226242524 creator A5023566983 @default.
• W4226242524 creator A5023608138 @default.
• W4226242524 creator A5023998116 @default.
• W4226242524 creator A5031060020 @default.
• W4226242524 creator A5033142433 @default.
• W4226242524 creator A5035484907 @default.
• W4226242524 creator A5044287124 @default.
• W4226242524 creator A5044644707 @default.
• W4226242524 creator A5047306995 @default.
• W4226242524 creator A5051087530 @default.
• W4226242524 creator A5055939495 @default.
• W4226242524 creator A5057108840 @default.
• W4226242524 creator A5058587876 @default.
• W4226242524 creator A5059967682 @default.
• W4226242524 creator A5061230192 @default.
• W4226242524 creator A5065077792 @default.
• W4226242524 creator A5067509381 @default.
• W4226242524 creator A5074765101 @default.
• W4226242524 creator A5077154021 @default.
• W4226242524 creator A5077529619 @default.
• W4226242524 creator A5083146903 @default.
• W4226242524 creator A5089398270 @default.
• W4226242524 creator A5091877145 @default.
• W4226242524 date "2022-06-14" @default.
• W4226242524 modified "2023-10-17" @default.
• W4226242524 title "Skeletal Muscle Disorders: A Noncardiac Source of Cardiac Troponin T" @default.
• W4226242524 cites W177502848 @default.
• W4226242524 cites W186995100 @default.
• W4226242524 cites W1901823973 @default.
• W4226242524 cites W1952836337 @default.
• W4226242524 cites W1959959904 @default.
• W4226242524 cites W1986599189 @default.
• W4226242524 cites W2000768570 @default.
• W4226242524 cites W2002420618 @default.
• W4226242524 cites W2013475362 @default.
• W4226242524 cites W2020715592 @default.
• W4226242524 cites W2059694151 @default.
• W4226242524 cites W2070594200 @default.
• W4226242524 cites W2073241303 @default.
• W4226242524 cites W2092048545 @default.
• W4226242524 cites W2098105324 @default.
• W4226242524 cites W2099464005 @default.
• W4226242524 cites W2112462515 @default.
• W4226242524 cites W2118129832 @default.
• W4226242524 cites W2130597202 @default.
• W4226242524 cites W2159335842 @default.
• W4226242524 cites W2164285209 @default.
• W4226242524 cites W2179438025 @default.
• W4226242524 cites W2185401965 @default.
• W4226242524 cites W2250152456 @default.
• W4226242524 cites W2523601922 @default.
• W4226242524 cites W2528223448 @default.
• W4226242524 cites W2530199167 @default.
• W4226242524 cites W2586517468 @default.
• W4226242524 cites W2599076725 @default.
• W4226242524 cites W2742891217 @default.
• W4226242524 cites W2754045762 @default.
• W4226242524 cites W2766202507 @default.
• W4226242524 cites W2779110724 @default.
• W4226242524 cites W2791638955 @default.
• W4226242524 cites W2795857347 @default.
• W4226242524 cites W2888543854 @default.
• W4226242524 cites W2888888319 @default.
• W4226242524 cites W2907104215 @default.
• W4226242524 cites W2944434778 @default.
• W4226242524 cites W2944687799 @default.
• W4226242524 cites W2955971301 @default.
• W4226242524 cites W2963478010 @default.
• W4226242524 cites W3003297978 @default.
• W4226242524 cites W3004717788 @default.
• W4226242524 cites W3010588636 @default.
• W4226242524 cites W3020874056 @default.
• W4226242524 cites W3162195278 @default.
• W4226242524 cites W3199537386 @default.
• W4226242524 cites W3207894029 @default.
• W4226242524 cites W4205129241 @default.
• W4226242524 cites W4238277289 @default.
• W4226242524 cites W4248429808 @default.
• W4226242524 cites W95923283 @default.
• W4226242524 doi "https://doi.org/10.1161/circulationaha.121.058489" @default.
• W4226242524 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35389756" @default.
• W4226242524 hasPublicationYear "2022" @default.
• W4226242524 type Work @default.
• W4226242524 citedByCount "22" @default.
• W4226242524 countsByYear W42262425242022 @default.
• W4226242524 countsByYear W42262425242023 @default.
• W4226242524 crossrefType "journal-article" @default.
• W4226242524 hasAuthorship W4226242524A5000794291 @default.
• W4226242524 hasAuthorship W4226242524A5006190744 @default.
• W4226242524 hasAuthorship W4226242524A5008204005 @default.

• next